Market Size of Global Cell Based Immunotherapy Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 15.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cell-Based Immunotherapy Market Analysis
The cell-based immunotherapy market is expected to register a CAGR of 15.5% during the forecast period.
COVID-19 had a significant impact on the cell-based immunotherapy market during the initial phases owing to the factors such as delayed elective surgeries, follow-up appointments, and some types of cancer treatments being canceled or postponed as hospitals prioritized beds and care for those patients who were seriously ill with COVID-19. For instance, as per an article published in March 2022 in PubMed, affected by the epidemic, many patients who were receiving subcutaneous immunotherapy (SCIT) were compelled to discontinue or postpone it.
Interestingly, cell-based immunotherapies were used for COVID-19 treatments during the pandemic. For instance, as per an article published in June 2022 in PubMed, innovative adaptive immune cell treatment gave patients with moderate-to-severe COVID-19 a viable preventative or therapeutic option. This strategy aimed to increase security, provide safe and efficient therapy, and supplement routine therapy for all COVID-19-infected patients. Post-pandemic, the market is anticipated to witness growth due to the rising prevalence of cancer, technological advancement in developing target-based anticancer therapy, and launches and approval of different cell-based immunotherapy.
For instance, as per an American Cancer Society 2022 update, the estimated number of new cancer cases was 1.9 million in 2022 in the United States. Additionally, the advancements in products, increasing approvals, clinical trials along with partnerships and collaborations by key players are helping the market growth. In June 2022 Immuneel Therapeutics, a biotech start-up commenced patient dosing in a CAR-T trial named IMAGINE. This phase II trial, which is currently actively enlisting patients in Bengaluru for clinical trial development, is one of the first industry-sponsored CAR-T trials in India. Such clinical trial developments are expected to augment the demand for cell-based immunotherapy. Furthermore, a rise in research and development in cell-based cancer therapy is likely to drive market growth over the forecast period. For instance, as per an article published in June 2022 in Frontiers, the majority of the current evaluation-stage strategies take advantage of the safety of T-cell activation and incorporate tumor-targeting mechanisms, such as chimeric antigen receptors (CARs) or bispecific T cell engagers (bsTCEs), which is likely to be essential to achieving more robust and reliable clinical responses.
Therefore, due to several factors, the cell-based immunotherapy market is anticipated to witness growth over the analysis period. However, the high cost of technology and lack of awareness in developing markets is likely to impede the market growth.
